Tecvayli (teclistamab)
Numéro de dossier de l’AMC:
22654
État des négociations:
Négociation envisagée
Indication(s):
Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy
Promoteur/fabricant:
Janssen Inc.
Numéro de projet de l’AMC:
PC0332-000
Lettre-contrat de l’APP:
Sans objet
Conclusion du processus de négociation:
Sans objet